Product Data Sheet

DRAK2-IN-1

Cat. No.: HY-122629 CAS No.: 871837-60-4 Molecular Formula: $C_{21}H_{20}N_4O_3$ Molecular Weight: 376.41 Target: DAPK Pathway: **Apoptosis**

Storage: Powder -20°C

3 years 2 years

-80°C 6 months In solvent

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (265.67 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6567 mL	13.2834 mL	26.5668 mL
	5 mM	0.5313 mL	2.6567 mL	5.3134 mL
	10 mM	0.2657 mL	1.3283 mL	2.6567 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (13.28 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (5.53 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	DRAK2-IN-1, compound 16, is a potent, selective and ATP-competitive DRAK2 inhibitor with IC $_{50}$ and K $_{i}$ values of 3 nM and 0.26 nM, respectively.DRAK2-IN-1 also has inbitory effect on DRAK1 (IC $_{50}$ =51 nM) $^{[1]}$.
IC ₅₀ & Target	IC50: 3 nM (DRAK2); 51 nM (DRAK1); 1.8 μ M (DRPK2); 2.3 μ M (DRAK2); 1.8 μ M (DRPK3) $^{[1]}$

REFERENCES

[1]. Jung ME, et al. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2719-23

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com